FireEye Launches New Mandiant Service to Help Address

New Post Public Reply Private Reply Replies (1) Message Board
4kids 4kids #163
FireEye Launches New Mandiant Service to Help Address Strategic Cyber Security Needs of Industrial Control Systems

Industrial Control Systems (ICS) HealthCheck -- A Security Assessment Combining Operational Technology and IT Security Expertise to Improve Detection and Response Capabilities in Critical Systems

MILPITAS, CA -- (Marketwired) -- 02/29/16 -- FireEye, Inc. (NASDAQ: FEYE), the leader in stopping today's advanced cyber attacks, today announced the launch of the Mandiant® ICS HealthCheck service, a minimally-invasive cyber security assessment for operators of mission-critical ICS. The ICS HealthCheck service is available now and is a core component of FireEye's continued focus on securing critical infrastructure.

ICS HealthCheck was specifically designed to meet the needs of asset owners concerned about the operational risk associated with software-based agents, network scanning or other security evaluation techniques. Mandiant's purpose-built methodology does not require any changes to the control system and does not generate network traffic that could disrupt normal operations. By modeling network architecture and data flows, using nation-state grade intelligence to simulate possible attacks, and prioritizing controls, organizations are able to better detect and respond to the unique threats their ICS environments face. This unique methodology bridges IT security and operational technology (OT) by enabling IT security teams and the engineering staff who manage ICS infrastructure to help create and identify joint solutions to identified vulnerabilities.

"The cyber security threats to ICS are becoming more tangible as threat actors expand beyond IP theft, cybercrime and espionage into ransomware, disruptive attacks and wiper malware," said Dan Scali, senior manager, ICS Security Consulting, FireEye. "The ICS HealthCheck is a critical service offering for any organization running ICS infrastructure, and, as part of the FireEye platform, allows customers to benefit from our intelligence on ICS-specific threats, strategically address risks, and reduce their time to detect and respond to threats."

Mandiant ICS HealthCheck customers receive the following tools:

Threat Model Diagram: a diagram of the ICS infrastructures -- including its interactions with the IT networks, ICS vendor networks, the Internet, and other access vectors -- overlaid with FireEye's ICS-specific intelligence to show how attackers could disrupt or degrade operations
ICS HealthCheck report: an overview of the technical flaws Mandiant identifies, including vulnerabilities, misconfigurations, or weaknesses, along with their risk priority
Technical & Strategic Recommendations: a presentation specifically designed to align IT and OT stakeholders at the technical and management levels around addressing the threats to their ICS infrastructure
As part of FireEye's initiative to secure ICS infrastructure, the Mandiant ICS HealthCheck along with the recently announced strategic partnership with Parsons bolsters the service portion of the FireEye platform. The recent acquisition of iSIGHT Partners has added deep intelligence capabilities around ICS to the FireEye platform while the newly announced strategic partnership with Belden adds ICS integrations to FireEye technologies.

More information on the Mandiant ICS HealthCheck can be found here:
https://www.fireeye.com/services/mandiant-ind...sment.html

For more information on the FireEye ICS initiatives please visit:
www.fireeye.com/blog/executive-perspective/2016/02/a_new_approach_tose.html

About FireEye, Inc.

FireEye has invented a purpose-built, virtual machine-based security platform that provides real-time threat protection to enterprises and governments worldwide against the next generation of cyber attacks. These highly sophisticated cyber attacks easily circumvent traditional signature-based defenses, such as next-generation firewalls, IPS, anti-virus, and gateways. The FireEye Threat Prevention Platform provides real-time, dynamic threat protection without the use of signatures to protect an organization across the primary threat vectors and across the different stages of an attack life cycle. The core of the FireEye platform is a virtual execution engine, complemented by dynamic threat intelligence, to identify and block cyber attacks in real time. FireEye has over 4,400 customers across 67 countries, including more than 680 of the Forbes Global 2000.

Forward-Looking Statements
This press release contains forward-looking statements, including statements related to the features, objectives and benefits of the Mandiant ICS HealthCheck service. These forward-looking statements involve risks and uncertainties, as well as assumptions which, if they do not fully materialize or prove incorrect, could cause the results of FireEye to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties that could cause such results to differ materially from those expressed or implied by such forward-looking statements include the ability of FireEye to retain and recruit highly experienced and qualified personnel; customer demand for and market acceptance of such offering; changes in the technology or the industries in which such offering is related; competitive pressures faced by FireEye; and general market, political, economic, and business conditions; as well as those risks and uncertainties included under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in FireEye's annual report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2016, which is available on the Investor Relations section of the company's website at investors.FireEye.com and on the SEC website at www.sec.gov. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and FireEye does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made. Any future service, feature, objective or benefit that may be referenced in this release is for information purposes only and is not a commitment to deliver any service, feature, objective or benefit. FireEye reserves the right to modify future plans at any time.

© 2016 FireEye, Inc. All rights reserved. FireEye, Mandiant and iSIGHT are registered trademarks or trademarks of FireEye, Inc. in the United States and other countries. All other brands, products or service names are or may be trademarks or service marks of their respective owners.

Source: FireEye

Mandiant, Inc. (MNDT) Stock Research Links

MNDT Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 19

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 14

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 11

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 10

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 20

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 17

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 8

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading

Top 5 Most Recently Viewed Articles

Sera Prognostics to Showcase Innovations at RBC Healthcare Event

Updated Category News Views 112

Sera Prognostics to Showcase Innovations at RBC Healthcare Event Sera Prognostics Inc., known as The Pregnancy Company (NASDAQ: SERA), is focused on enhancing maternal and neonatal health through innovative pregnancy biomarker information. The company has recently announced its participation at an important healthcare event, highlighting its ongoing commitment to improve...

Continue Reading
Unlocking AI Potential: Insights from Netcracker CEO Andrew Feinberg

Updated Category News Views 268

Exciting Keynote at GITEX Global 2024 Netcracker Technology is buzzing with excitement as Andrew Feinberg, the Chairman and CEO, prepares for a pivotal keynote presentation at one of the largest tech events in the world, GITEX Global 2024. This annual technology conference draws innovators, industry leaders, and enthusiasts keen on understanding the future of technology....

Continue Reading
Adherium Empowers COPD and Asthma Management with iCARE Study

Updated Category News Views 147

Adherium's Transformative iCARE Study Results The innovative strides made by Adherium Limited (ASX:ADR) in respiratory health have shown promising outcomes as seen in the iCARE study. This study investigated the effectiveness of their Hailie® Smartinhaler® technology in improving adherence among patients suffering from chronic obstructive pulmonary disease (COPD) and...

Continue Reading
Medius Highlights Impending Finance Challenges Post AI Launch

Updated Category News Views 243

AI Fraud Concerns Elevate in the Finance Sector Medius has unveiled alarming findings indicating that nearly one in three finance professionals are unable to spot AI-generated fake receipts. This revelation surfaces amidst rising fears of fraud escalation following the recent launch of GPT-5.0. With the capabilities of AI continuously improving, finance teams must prepare...

Continue Reading
TD Cowen Sustainably Endorses Abbott Labs with Robust Price Target

Updated Category News Views 59

TD Cowen Affirms Buy Rating on Abbott Laboratories TD Cowen has reaffirmed its Buy rating on Abbott Laboratories (NYSE: ABT), maintaining a price target of $130.00 for the healthcare company's shares. This positive stance hinges on expectations that Abbott's upcoming third-quarter results will either meet or surpass current market predictions, allowing the company to...

Continue Reading